Cyxone in media
BioStock article: Cyxone focuses on the RA programme
BioStock published an article on 20 May 2022 about Cyxone, which can be read in full below. First North-listed Cyxone recently published its Q1 report, a period during which the company carried out a rights issue of 61 MSEK,...
Read MoreBioStock article: RA patients in great need of new treatment options
BioStock published an article on 5 May 2022 about the great need of new treatment options for RA patients. Following the FDA’s safety warnings, a shift is seen away from JAK inhibitors for the treatment of rheumatoid arthritis. The...
Read MoreBioStock article: Cyxone about the advancements in the T20K project
BioStock published an article on 7 February 2022 about Cyxone, which can be read in full below. Biotech company Cyxone recently announced the next step in the T20K project, their drug candidate for multiple sclerosis. The company has signed...
Read MoreBioStock article: Cyxone’s CRO agreement signal phase IIb RA trial is moving forward as planned
BioStock published an article on 20 December 2021 about Cyxone, which can be read in full below. In the preparation for the coming phase IIb trial with Rabeximod in rheumatoid arthritis, biotech company Cyxone has entered an Early Operations...
Read MoreBioStock article: Pre-clinical data indicates wider use for Cyxone’s T20K in MS
BioStock published an article on 8 November 2021 about Cyxone, which can be read in full below. Biotech company Cyxone is developing T20K, a drug candidate with first-in-class potential for the treatment of multiple sclerosis. Recently, Cyxone’s research partner,...
Read MoreBioStock article: Eight CEOs on their expectations at BIO-Europe
It is time for 2021’s edition of the largest partnering meeting in the life science space – BIO-Europe. This week, representatives from nearly 1,500 companies will gather to establish new contacts as well as continue initiated discussions with potential...
Read MoreBioStock article: Cyxone has closed recruitment to the phase II Covid-19 trial
BioStock published an article on 16 August 2021 about Cyxone, which can be read in full below. Swedish biotech Cyxone announced last month that the patient recruitment for its phase II trial testing Rabeximod in Covid-19 could come to...
Read MoreBioStock article: Cyxone is exploring new treatment possibilities for T20K
BioStock published an article on 15 July 2021 about Cyxone, which can be read in full below. After identifying new therapeutic treatment possibilities for T20K, Cyxone has announced a research collaboration with the Medical University of Vienna to further...
Read MoreBioStock article: New COO brings extensive immunology experience to Cyxone
BioStock published an article on 14 June 2021 about Cyxone, which can be read in full below. During May, Swedish biotech company Cyxone released a string of news. Recently, the company announced the recruitment of Carl-Magnus Högerkorp as new...
Read MoreBioStock article: Spotlight on MS
BioStock published an article on 28 May 2021 about Cyxone, which can be read in full below. World MS Day will be celebrated on Sunday May 30th. It is a day to raise awareness of the condition, and to...
Read More